HIV cure and eradication: how will we get from the laboratory to effective clinical trials?
Identifieur interne : 006A62 ( Main/Exploration ); précédent : 006A61; suivant : 006A63HIV cure and eradication: how will we get from the laboratory to effective clinical trials?
Auteurs : Sharon R. Lewin [Australie] ; Christine Rouzioux [France]Source :
- AIDS : (London) [ 0269-9370 ] ; 2011.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Combination antiretroviral therapy (cART) has led to a major reduction in HIV-related mortality and morbidity; however, HIV can still not be cured. Achieving either a functional cure (long-term control of HIV in the absence of cART) or a sterilizing cure (elimination of all HIV-infected cells) remains a major challenge. The most significant barrier to cure is the establishment of a latent or 'silent' infection in resting CD4+ T cells. Several randomized clinical trials have demonstrated that treatment intensification with additional antiretrovirals has little impact on latent reservoirs. Some potential other approaches that may reduce the latent reservoir include very early initiation of cART and the use of agents that could reverse latent infection. Drugs such as histone deacetylase inhibitors, currently used and licensed for the treatment of some cancers; methylation inhibitors; cytokines such as IL-7 or activators of nuclear factor kappa B (NF-κB) such as prostratin, show promising activity in reversing latency in vitro when used either alone or in combination. Alternate strategies include using gene therapy to modify expression of CCR5 and therefore make cells resistant to HIV. This review will primarily focus on the advantages and disadvantages of methods currently being used to quantify persistent virus ex vivo in patients receiving cART and strategies aimed at cure that are beingtested in vitro or in early clinical development. In addition, we discuss key issues that need to be addressed to successfully move laboratory research to clinical trials aimed at curing HIV.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 001D44
- to stream PascalFrancis, to step Curation: 004198
- to stream PascalFrancis, to step Checkpoint: 001A48
- to stream Main, to step Merge: 006E99
- to stream Main, to step Curation: 006A62
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">HIV cure and eradication: how will we get from the laboratory to effective clinical trials?</title><author><name sortKey="Lewin, Sharon R" sort="Lewin, Sharon R" uniqKey="Lewin S" first="Sharon R." last="Lewin">Sharon R. Lewin</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Infectious Diseases Unit, Alfred Hospital</s1><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Infectious Diseases Unit, Alfred Hospital</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of medicine, Monash University</s1><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Department of medicine, Monash University</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Centre for Virology, Burnet Institute, Melbourne</s1><s2>Victoria</s2><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Rouzioux, Christine" sort="Rouzioux, Christine" uniqKey="Rouzioux C" first="Christine" last="Rouzioux">Christine Rouzioux</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Laboratory of Virology, Hôpital Necker</s1><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Hôpital Necker</wicri:noRegion><wicri:noRegion>Laboratory of Virology, Hôpital Necker</wicri:noRegion></affiliation><affiliation wicri:level="4"><inist:fA14 i1="05"><s1>EA 3620 Université Paris Descartes</s1><s2>Paris</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement><settlement type="city">Paris</settlement></placeName><orgName type="university">Université Paris-Descartes</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">11-0242946</idno><date when="2011">2011</date><idno type="stanalyst">PASCAL 11-0242946 INIST</idno><idno type="RBID">Pascal:11-0242946</idno><idno type="wicri:Area/PascalFrancis/Corpus">001D44</idno><idno type="wicri:Area/PascalFrancis/Curation">004198</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001A48</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001A48</idno><idno type="wicri:doubleKey">0269-9370:2011:Lewin S:hiv:cure:and</idno><idno type="wicri:Area/Main/Merge">006E99</idno><idno type="wicri:Area/Main/Curation">006A62</idno><idno type="wicri:Area/Main/Exploration">006A62</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">HIV cure and eradication: how will we get from the laboratory to effective clinical trials?</title><author><name sortKey="Lewin, Sharon R" sort="Lewin, Sharon R" uniqKey="Lewin S" first="Sharon R." last="Lewin">Sharon R. Lewin</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Infectious Diseases Unit, Alfred Hospital</s1><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Infectious Diseases Unit, Alfred Hospital</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of medicine, Monash University</s1><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>Department of medicine, Monash University</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Centre for Virology, Burnet Institute, Melbourne</s1><s2>Victoria</s2><s3>AUS</s3><sZ>1 aut.</sZ></inist:fA14><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Rouzioux, Christine" sort="Rouzioux, Christine" uniqKey="Rouzioux C" first="Christine" last="Rouzioux">Christine Rouzioux</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Laboratory of Virology, Hôpital Necker</s1><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country><wicri:noRegion>Hôpital Necker</wicri:noRegion><wicri:noRegion>Laboratory of Virology, Hôpital Necker</wicri:noRegion></affiliation><affiliation wicri:level="4"><inist:fA14 i1="05"><s1>EA 3620 Université Paris Descartes</s1><s2>Paris</s2><s3>FRA</s3><sZ>2 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement><settlement type="city">Paris</settlement></placeName><orgName type="university">Université Paris-Descartes</orgName></affiliation></author></analytic><series><title level="j" type="main">AIDS : (London)</title><title level="j" type="abbreviated">AIDS : (Lond.)</title><idno type="ISSN">0269-9370</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">AIDS : (London)</title><title level="j" type="abbreviated">AIDS : (Lond.)</title><idno type="ISSN">0269-9370</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS</term><term>Clinical trial</term><term>Cure</term><term>Eradication</term><term>Human immunodeficiency virus</term><term>Laboratory</term><term>Latency</term><term>Reservoir</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>SIDA</term><term>Guérison</term><term>Eradication</term><term>Laboratoire</term><term>Virus immunodéficience humaine</term><term>Essai clinique</term><term>Latence</term><term>Réservoir</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Combination antiretroviral therapy (cART) has led to a major reduction in HIV-related mortality and morbidity; however, HIV can still not be cured. Achieving either a functional cure (long-term control of HIV in the absence of cART) or a sterilizing cure (elimination of all HIV-infected cells) remains a major challenge. The most significant barrier to cure is the establishment of a latent or 'silent' infection in resting CD4<sup>+</sup> T cells. Several randomized clinical trials have demonstrated that treatment intensification with additional antiretrovirals has little impact on latent reservoirs. Some potential other approaches that may reduce the latent reservoir include very early initiation of cART and the use of agents that could reverse latent infection. Drugs such as histone deacetylase inhibitors, currently used and licensed for the treatment of some cancers; methylation inhibitors; cytokines such as IL-7 or activators of nuclear factor kappa B (NF-κB) such as prostratin, show promising activity in reversing latency in vitro when used either alone or in combination. Alternate strategies include using gene therapy to modify expression of CCR5 and therefore make cells resistant to HIV. This review will primarily focus on the advantages and disadvantages of methods currently being used to quantify persistent virus ex vivo in patients receiving cART and strategies aimed at cure that are beingtested in vitro or in early clinical development. In addition, we discuss key issues that need to be addressed to successfully move laboratory research to clinical trials aimed at curing HIV.</div></front></TEI><affiliations><list><country><li>Australie</li><li>France</li></country><region><li>Victoria (État)</li><li>Île-de-France</li></region><settlement><li>Melbourne</li><li>Paris</li></settlement><orgName><li>Université Paris-Descartes</li></orgName></list><tree><country name="Australie"><noRegion><name sortKey="Lewin, Sharon R" sort="Lewin, Sharon R" uniqKey="Lewin S" first="Sharon R." last="Lewin">Sharon R. Lewin</name></noRegion><name sortKey="Lewin, Sharon R" sort="Lewin, Sharon R" uniqKey="Lewin S" first="Sharon R." last="Lewin">Sharon R. Lewin</name><name sortKey="Lewin, Sharon R" sort="Lewin, Sharon R" uniqKey="Lewin S" first="Sharon R." last="Lewin">Sharon R. Lewin</name></country><country name="France"><noRegion><name sortKey="Rouzioux, Christine" sort="Rouzioux, Christine" uniqKey="Rouzioux C" first="Christine" last="Rouzioux">Christine Rouzioux</name></noRegion><name sortKey="Rouzioux, Christine" sort="Rouzioux, Christine" uniqKey="Rouzioux C" first="Christine" last="Rouzioux">Christine Rouzioux</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006A62 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006A62 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:11-0242946
|texte= HIV cure and eradication: how will we get from the laboratory to effective clinical trials?
}}
| This area was generated with Dilib version V0.6.33. |  |